IN2012DN00954A - - Google Patents

Info

Publication number
IN2012DN00954A
IN2012DN00954A IN954DEN2012A IN2012DN00954A IN 2012DN00954 A IN2012DN00954 A IN 2012DN00954A IN 954DEN2012 A IN954DEN2012 A IN 954DEN2012A IN 2012DN00954 A IN2012DN00954 A IN 2012DN00954A
Authority
IN
India
Prior art keywords
compound
methyl
salt
tablet
content
Prior art date
Application number
Inventor
Murakawa Yusuke
Okabe Takayuki
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43529294&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2012DN00954(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of IN2012DN00954A publication Critical patent/IN2012DN00954A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/12—Ophthalmic agents for cataracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Inorganic Chemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Communicable Diseases (AREA)
  • Rheumatology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Provided is a tablet having a high content of 2—[[6— [ (3R)-3-amino-l-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-4-fluorobenzonitrile (compound (A)) or a salt thereof as a pharmaceutically active component. A tablet containing compound (A) or a salt thereof, and a fluidizer, which has a compound (A) content of 35 - 50 weight%.
IN954DEN2012 2009-07-28 2010-07-27 IN2012DN00954A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009175695 2009-07-28
PCT/JP2010/062568 WO2011013639A1 (en) 2009-07-28 2010-07-27 Tablet

Publications (1)

Publication Number Publication Date
IN2012DN00954A true IN2012DN00954A (en) 2015-04-10

Family

ID=43529294

Family Applications (1)

Application Number Title Priority Date Filing Date
IN954DEN2012 IN2012DN00954A (en) 2009-07-28 2010-07-27

Country Status (23)

Country Link
US (1) US20120129878A1 (en)
EP (1) EP2460523B1 (en)
JP (1) JP5732394B2 (en)
KR (1) KR20120039046A (en)
CN (1) CN102548556A (en)
AU (1) AU2010279171A1 (en)
BR (1) BR112012001959A2 (en)
CA (1) CA2769177A1 (en)
CL (1) CL2012000182A1 (en)
CO (1) CO6612226A2 (en)
CR (1) CR20120061A (en)
EA (1) EA201270204A1 (en)
EC (1) ECSP12011699A (en)
IL (1) IL217560A0 (en)
IN (1) IN2012DN00954A (en)
MA (1) MA33539B1 (en)
MX (1) MX2012001284A (en)
PE (1) PE20120919A1 (en)
SG (1) SG178062A1 (en)
TN (1) TN2012000031A1 (en)
TW (1) TW201106991A (en)
WO (1) WO2011013639A1 (en)
ZA (1) ZA201200761B (en)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5874545B2 (en) * 2011-06-20 2016-03-02 アステラス製薬株式会社 Pharmaceutical composition for oral administration
KR102145641B1 (en) 2012-06-05 2020-08-18 다케다 야쿠힌 고교 가부시키가이샤 Solid preparation
CN103768071B (en) * 2012-10-23 2016-08-17 中国医药工业研究总院 A kind of oral formulations treating diabetes
CN103877054B (en) * 2012-12-21 2016-05-25 北大方正集团有限公司 A kind of SYR-322 tablet and preparation method thereof
CN105078974A (en) * 2014-05-23 2015-11-25 深圳信立泰药业股份有限公司 Allisartan isoproxil solid dispersion and pharmaceutical composition
US20160331689A1 (en) * 2015-05-12 2016-11-17 SE Tylose USA, Inc. Aqueous enteric coating composition
CN105596341B (en) * 2016-03-14 2018-08-10 石家庄四药有限公司 A kind of amber love song Ge Lieting solid pharmaceutical preparations and preparation method
US11033501B2 (en) 2016-05-10 2021-06-15 Nippon Zoki Pharmaceutical Co., Ltd. Method for manufacturing acetaminophen preparation
CN120112021A (en) * 2020-08-28 2025-06-06 群创光电股份有限公司 Light emitting unit
CN116763752B (en) * 2023-08-24 2023-11-17 北京福元医药股份有限公司 Acarbose tablet and preparation method thereof

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585115A (en) * 1995-01-09 1996-12-17 Edward H. Mendell Co., Inc. Pharmaceutical excipient having improved compressability
WO1997010224A1 (en) 1995-09-13 1997-03-20 Takeda Chemical Industries, Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
JP2711528B2 (en) * 1995-12-20 1998-02-10 大洋薬品工業株式会社 Loxoprofen preparation
AR035016A1 (en) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd COMPOSITION OF AZOL PROMOTER OF PRODUCTION / SECRETION OF NEUROTROFINE, COMPOSITE PRODROGA OF THE SAME, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND USE OF THE SAME TO PREPARE THIS LAST.
AU2001269531A1 (en) 2000-07-17 2002-01-30 Takeda Chemical Industries Ltd. Sulfone derivatives, process for their production and use thereof
KR20050062645A (en) 2002-11-01 2005-06-23 다케다 야쿠힌 고교 가부시키가이샤 Agent for preventing or treating neuropathy
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
EP1564213A4 (en) 2002-11-22 2009-05-27 Takeda Pharmaceutical IMIDAZOLE DERIVATIVES, PROCESS FOR THE PRODUCTION AND USE THEREOF
US7820837B2 (en) 2003-05-30 2010-10-26 Takeda Pharmaceutical Company Limited Condensed ring compound
EP1669352A4 (en) 2003-09-30 2008-12-17 Takeda Pharmaceutical THIAZOLINE DERIVATIVE AND USE
WO2005058823A1 (en) 2003-12-17 2005-06-30 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
BRPI0418148A (en) 2003-12-25 2007-04-17 Takeda Pharmaceutical compound, prodrug of a compound, gpr40 receptor function modulator, pharmaceutical agent, use of a compound and methods of modifying a gpr40 receptor function in a mammal, prophylaxis or treating diabetes in a mammal and producing a compound
JP4855777B2 (en) 2003-12-26 2012-01-18 武田薬品工業株式会社 Phenylpropanoic acid derivatives
WO2005095381A1 (en) 2004-03-15 2005-10-13 Takeda Pharmaceutical Company Limited Dipeptidyl peptidase inhibitors
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
EP1731505B1 (en) 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
TWI396686B (en) 2004-05-21 2013-05-21 Takeda Pharmaceutical Cyclic guanamine derivatives, as well as their products and usage
JP4919252B2 (en) * 2004-08-05 2012-04-18 株式会社明治 Granular preparation and method for producing the same
CA2605778A1 (en) 2005-04-20 2006-10-26 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
DK1897558T3 (en) * 2005-06-09 2013-12-09 Norgine Bv SOLID PREPARATION OF 2-HEXADECYLOXY-6-METHYL-4H-3,1-BENZOXAZIN-4-ON
WO2007013689A1 (en) 2005-07-29 2007-02-01 Takeda Pharmaceutical Company Limited Cyclopropanecarboxylic acid compound
US20090054435A1 (en) 2005-07-29 2009-02-26 Hiroshi Imoto Phenoxyalkanoic Acid Compound
CN101282725A (en) 2005-08-10 2008-10-08 武田药品工业株式会社 Therapeutic agent for diabetes
JP2007063225A (en) 2005-09-01 2007-03-15 Takeda Chem Ind Ltd Imidazopyridine compound
JP2007211005A (en) * 2006-01-16 2007-08-23 Ono Pharmaceut Co Ltd Composition for solid preparation and solid preparation
CA2656003C (en) 2006-06-27 2014-03-25 Tsuneo Yasuma Fused cyclic compounds
JP5791228B2 (en) 2006-09-13 2015-10-07 武田薬品工業株式会社 Use of 2-6- (3-amino-piperidin-1-yl) -3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile
EP2298772A1 (en) 2006-10-18 2011-03-23 Takeda Pharmaceutical Company Limited Fused heterocyclic compounds
MY158052A (en) 2006-10-19 2016-08-30 Takeda Pharmaceutical Indole compound
JPWO2008093639A1 (en) 2007-01-29 2010-05-20 武田薬品工業株式会社 Pyrazole compounds
WO2008093878A1 (en) * 2007-02-01 2008-08-07 Takeda Pharmaceutical Company Limited Tablet preparation without causing a tableting trouble
CN101646653A (en) 2007-02-09 2010-02-10 武田药品工业株式会社 Fused ring compounds as partial agonists of ppar-gamma
WO2008114800A2 (en) * 2007-03-13 2008-09-25 Takeda Pharmaceutical Company Limited Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidinyl] -3, 4-dihydro-3-methyl-2, 4-dioxo-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile
WO2008136428A1 (en) 2007-04-27 2008-11-13 Takeda Pharmaceutical Company Limited Nitrogen-containing five-membered heterocyclic compound
US20110301155A1 (en) 2007-06-19 2011-12-08 Tsuneo Yasuma Indazole compounds for activating glucokinase
US8400391B2 (en) 2008-01-10 2013-03-19 Honeywell International Inc. Method and system for improving dimming performance in a field sequential color display device

Also Published As

Publication number Publication date
MA33539B1 (en) 2012-08-01
CL2012000182A1 (en) 2012-10-12
CA2769177A1 (en) 2011-02-03
PE20120919A1 (en) 2012-08-13
JP5732394B2 (en) 2015-06-10
IL217560A0 (en) 2012-02-29
CO6612226A2 (en) 2013-02-01
KR20120039046A (en) 2012-04-24
TW201106991A (en) 2011-03-01
BR112012001959A2 (en) 2016-03-15
CR20120061A (en) 2012-03-06
ECSP12011699A (en) 2012-03-30
EP2460523A1 (en) 2012-06-06
US20120129878A1 (en) 2012-05-24
SG178062A1 (en) 2012-03-29
MX2012001284A (en) 2012-03-26
TN2012000031A1 (en) 2013-09-19
EP2460523B1 (en) 2017-01-04
CN102548556A (en) 2012-07-04
EA201270204A1 (en) 2012-08-30
EP2460523A4 (en) 2014-02-26
WO2011013639A1 (en) 2011-02-03
AU2010279171A1 (en) 2012-03-01
JPWO2011013639A1 (en) 2013-01-07
ZA201200761B (en) 2013-05-29

Similar Documents

Publication Publication Date Title
IN2012DN00954A (en)
MX2009009703A (en) Solid preparation comprising 2- [ [6- [ (3r) -3-amino-1-piperidin yl] -3, 4-dihydr0-3-methyl-2, 4-di0x0-1 (2h) -pyrimidinyl] methyl] -4-fluorobenzonitrile.
TW200801000A (en) Spiroindolinone derivatives
MX2007004699A (en) Indole and benzimidazole derivatives.
TW200612958A (en) Substituted imidazole derivatives
MX2010004576A (en) Novel pyrimidine derivatives.
JO2761B1 (en) 1Phenyl-2-Pyridinyl Alkyl Alcohol Derivatives As Phosphodiesterase Inhibitors
MX2009004746A (en) 1,2,4-triazole derivatives as sigma receptor inhibitors.
UA105229C2 (en) Pharmaceutical formulation
TN2010000044A1 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
MY151295A (en) Pyrimidyl indoline compound
WO2009082152A3 (en) Glucokinase activators and pharmaceutical compositions containing the same as an active ingredient
UA104885C2 (en) Isothiazolyloxyphenyl amidines and use thereof as fungicides
MX2011012739A (en) Fluorinated aminotriazole derivatives.
MX2011012523A (en) Ketal esters of anhydropentitols and uses thereof.
MY147188A (en) Substituted imidazole compounds as ksp inhibitors
GEP20156242B (en) 2-arylimidazole derivatives as pde10a enzyme inhibitors
TN2009000287A1 (en) Cyclized derivatives as eg-5inhibitors
MY161461A (en) Akt and p70 s6 kinase inhibitors
PL1753723T3 (en) Substituted quinoline derivatives as mitotic kinesin inhibitors
MX2013006420A (en) Hydroxylated aminotriazole derivatives as alx receptor agonists.
MY152040A (en) Triazolopyridazines as par1 inhibitors, production thereof, and use as medicaments
MY148732A (en) Triazolium salts as par1 inhibitors, production thereof, and use as medicaments
WO2009097973A3 (en) Imidazopyridazines as par1 inhibitors, production thereof, and use thereof as medicaments
MX2009006266A (en) Processes for the preparation of 3-(4-(2,4-difluorobenzyloxy)-3-b romo-6-methyl-2-oxopyridin-1(2h)-yl)-n,4-dimethylbenzamide.